The challenges of carbapenemase-producing Enterobacteriaceae and infection prevention: Protecting patients in the chaos

Infection Control and Hospital Epidemiology

Volumn 34, Issue 7, 2013, Pages 730-739

  Savard, Patrice ^a,b   Carroll, Karen C ^c   Wilson, Lucy E ^d   Perl, Trish M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d MARYLAND DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; CARBAPENEMASE;

ARTICLE; AUTHORITY; BACTERIAL TRANSMISSION; BACTERIUM ISOLATION; DISEASE SURVEILLANCE; ENTEROBACTERIACEAE INFECTION; HEALTH CARE PERSONNEL; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; LABORATORY; PREVALENCE; RISK FACTOR;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; CROSS INFECTION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; PATIENT ISOLATION;

EID: 84878750270     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/671003     Document Type: Article

References (73)

1. Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrob Agents Chemother Mar 2010;54(3):969-976.
2. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983;11(6):315-317.
3. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005;18(4):657-686.
4. Philippon A, Labia R, Jacoby G. Extended-spectrum β-lactamases. Antimicrob Agents Chemother 1989;33(8):1131-1136.
5. Bartlett JG. A call to arms: the imperative for antimicrobial stewardship. Clin Infect Dis 2011;53(suppl 1):S4-S7.
6. Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 2007;20(3):440-458.
7. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenemhydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001;45(4):1151-1161.
8. Arnold RS, Thom KA, Sharma S, Phillips M, Johnson JK, Morgan DJ. Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria. South Med J 2011;104(1):40-45.
9. Cornaglia G, Giamarellou H, Rossolini GM. Metallo-β-lactamases: a last frontier for β-lactams? Lancet Infect Dis 2011;11(5): 381-393.
10. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10(9):597-602.
11. Centers for Disease Control and Prevention. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. Morb Mortal Wkly Rep 2009;58(10):256-260.
12. World Health Organization. The evolving threat of antimicrobial resistance: options for action. http://www.who.int/patientsafety/implementation/amr/publication/en/.
13. Savard P, Perl TM. A call for action: managing the emergence of multidrug-resistant Enterobacteriaceae in the acute care settings. Curr Opin Infect Dis 2012;25(4):371-377.
14. Kallen AJ, Srinivasan A. Current epidemiology of multidrug-resistant gram-negative bacilli in the United States. Infect Control Hosp Epidemiol 2010;31(suppl 1):S51-S54.
15. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011;53(1):60-67.
16. Cagnacci S, Gualco L, Roveta S, et al. Bloodstream infections caused by multidrug-resistant Klebsiella pneumoniae producing the carbapenem-hydrolysing VIM-1 metallo-β-lactamase: first Italian outbreak. J Antimicrob Chemother 2008;61(2):296-300.
17. Tato M, Coque TM, Ruiz-Garbajosa P, et al. Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-β-lactamase in Spain: toward endemicity? Clin Infect Dis 2007;45(9):1171-1178.
18. Vatopoulos A. High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece: a review of the current evidence. Euro Surveill 2008;13(4):pii= 8023.
19. Canton R, Akova M, Carmeli Y, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012;18(5):413-431.
20. Prior AR, Roche C, Lynch M, Kelly S, O'Rourke K, Crowley B. First identified case of VIM-producing carbapenem-resistant Klebsiella pneumoniae in the Republic of Ireland associated with fatal outcome. Euro Surveill 2010;15(50):pii = 19752.
21. Samuelsen Ø, Toleman MA, Hasseltvedt V, et al. Molecular characterization of VIM-producing Klebsiella pneumoniae from Scandinavia reveals genetic relatedness with international clonal complexes encoding transferable multidrug resistance. Clin Microbiol Infect 2011;17(11):1811-1816.
22. Kristóf K, Tóth Á, Damjanova I, et al. Identification of a blaVIM-4 gene in the internationally successful Klebsiella pneumoniae ST11 clone and in a Klebsiella oxytoca strain in Hungary. J Antimicrob Chemother 2010;65(6):1303-1305.
23. Montealegre MC, Correa A, Briceño DF, et al. Novel VIM metallo-β-lactamase variant, VIM-24, from a Klebsiella pneumonia isolate from Colombia. Antimicrob Agents Chemother 2011; 55(5):2428-2430.
24. Centers for Disease Control and Prevention. Update: detection of a Verona integron-encoded metallo-beta-lactamase in Kleβ-siella pneumoniae-United States, 2010. Morb Mortal Wkly Rep 2010;59(37):1212.
25. Limbago BM, Rasheed JK, Anderson KF, et al. IMP-producing carbapenem-resistant Klebsiella pneumoniae in the United States. J Clin Microbiol 2011;49(12):4239-4245.
26. Struelens MJ, Monnet DL, Magiorakos AP, Santos O'Connor F, Giesecke J. New Delhi metallo-beta-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. Euro Surveill 2010;15(46):pii = 19716.
27. Perry JD, Naqvi SH, Mirza IA, et al. Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. J Antimicrob Chemother 2011;66(10):2288-2294.
28. Rolain JM, Parola P, Cornaglia G. New Delhi metallo-beta-lactamase (NDM-1): towards a new pandemia? Clin Microbiol Infect 2010;16(12):1699-1701.
29. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. Trends Microbiol 2011;19(12):588-595.
30. Walsh TR. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents 2010;36(suppl 3):S8-S14.
31. Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P. Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. Antimicrob Agents Chemother 2010; 54(11):4914-4916.
32. Tijet N, Alexander DC, Richardson D, et al. New Delhi metallo-β-lactamase, Ontario, Canada. Emerg Infect Dis 2011;17(2):306-307.
33. Centers for Disease Control and Prevention. Carbapenem-resistant Enterobacteriaceae containing New Delhi metallo-beta-lactamase in two patients-Rhode Island, March 2012. Morb Mortal Wkly Rep 2012;61(24):446-448.
34. Savard P, Gopinath R, Zhu W, et al. First NDM-positive Salmonella sp. strain identified in the United States. Antimicrob Agents Chemother 2011;55(12):5957-5958.
35. Centers for Disease Control and Prevention. Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase-United States, 2010 Morb Mortal Wkly Rep 2010;59(24):750.
36. Mochon AB, Garner OB, Hindler JA, et al. New Delhi metallo-β-lactamase (NDM-1)-producing Klebsiella pneumoniae: case report and laboratory detection strategies. J Clin Microbiol 2011; 49(4):1667-1670.
37. Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P. Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. Antimicrob Agents Chemother 2010; 54(11):4914-4916.
38. Gregory CJ, Llata E, Stine N, et al. Outbreak of carbapenem-resistant Klebsiella pneumoniae in Puerto Rico associated with a novel carbapenemase variant. Infect Control Hosp Epidemiol 2010;31(5):476-484.
39. Poirel L, Hervé V, Hombrouck-Alet C, Nordmann P. Long-term carriage of NDM-1-producing Escherichia coli. J Antimicrob Chemother 2011;66(9):2185-2186.
40. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9(4):228-236.
41. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Out-comes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29(12):1099-1106.
42. Souli M, Galani I, Antoniadou A, et al. An outbreak of infection due to β-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 2010;50(3):364-373.
43. Livermore D, Department of Health Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection. Advice on carbapenemase producers: recognition, infection control and treatment. Health Protection Agency website. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1294740725984. Published 2011.
44. Public Health Agency of Canada. Guidance: infection prevention and control measures for healthcare workers in all healthcare settings. Carbapenem-resistant gram-negative bacilli. http://www.phac-aspc.gc.ca/nois-sinp/guide/ipcm-mpci/pdf/guide-eng.pdf. Published 2010.
45. CINQ (Comité sur les infections nosocomiales du Québec). Avis et recommandations: prévention et contrôle de la transmission des entérobactéries productrices de carbapénémases dans les milieux de soins aigus du Québec. Institut National de Santé Publique du Québec website. http://www.inspq.qc.ca/pdf/publications/1168_PreventionTransmissionEnterobactCarbapenemases.pdf. Published October 2010.
46. Haut Conseil de la santé publique. Maîtrise de la diffusion des bactéries multirésistantes aux antibiotiques importées en France par des patients rapatriés ou ayant des antécédents d'hospitalisation à l'étranger. 2nd version. http://www.hcsp.fr/docspdf/avisrapports/hcspr20101116_bmrimport.pdf. Published November 2010.
47. Carmeli Y, Akova M, Cornaglia G, et al. Controlling the spread of carbapenemase-producing gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect 2010;16(2): 102-111.
48. Grundmann H, Livermore DM, Giske CG, et al. Carbapenemnon-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill 2010;15(46): pii = 19711.
49. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Healthcare Quality Promotion. Guidance for control of carbapenem-resistant Enterobacteriaceae (CRE). 2012 CRE toolkit. http://www.cdc.gov/hai/organisms/cre/cre-toolkit/index.html. Updated March 5, 2013.
50. Kollef MH, Golan Y, Micek ST, Shorr AF, Restrepo MI. Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections: proceedings and data from the Gram-Negative Resistance Summit. Clin Infect Dis 2011; 53(suppl 2):S33-S58.
51. Wendt C, Schutt S, Dalpke AH, et al. First outbreak of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumonia in Germany. Eur J Clin Microbiol Infect Dis 2010;29(5):563-570.
52. Doern CD, Dunne WM Jr, Burnham CA. Detection of Klebsiella pneumoniae carbapenemase (KPC) production in non-Klebsiella pneumoniae Enterobacteriaceae isolates by use of the Phoenix, Vitek 2, and disk diffusion methods. J Clin Microbiol 2011;49(3): 1143-1147.
53. Clinical and Laboratory Standards Institute (CLSI). 2010. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement (June 2010 update). Wayne, PA: CLSI, 2010. CLSI document M100-S20-U.
54. Pasteran F, Lucero C, Soloaga R, Rapoport M, Corso A. Can we use imipenem and meropenem Vitek 2 MICs for detection of suspected KPC and other-carbapenemase producers among species of Enterobacteriaceae? J Clin Microbiol 2011;49(2):697-701.
55. Seah C, Low DE, Patel SN, Melano RG. Comparative evaluation of a chromogenic agar medium, the modified Hodge test, and a battery of meropenem-inhibitor discs for detection of carbapenemase activity in Enterobacteriaceae. J Clin Microbiol 2011; 49(5):1965-1969.
56. Girlich D, Poirel L, Nordmann P. Value of the modified Hodge test for detection of emerging carbapenemases in Enterobacteriaceae. J Clin Microbiol 2012;50(2):477-479.
57. Nordmann P, Girlich D, Poirel L. Detection of carbapenemase producers in Enterobacteriaceae using a novel screening medium. J Clin Microbiol 2012;50:(8):2761-2766.
58. Vrioni G, Daniil I, Voulgari E, et al. Comparative evaluation of a prototype chromogenic medium (chromID CARBA) for detecting carbapenemase-producing Enterobacteriaceae in surveillance rectal swabs. J Clin Microbiol 2012;50(6):1841-1846.
59. Wilkinson KM, Winstanley TG, Lanyon C, Cummings SP, Raza MW, Perry JD. Comparison of four chromogenic culture media for carbapenemase-producing Enterobacteriaceae. J Clin Microbiol 2012;50(9):3102-3104.
60. Siegel JD, Rhinehart E, Jackson M, et al. Management of multidrug-resistant organisms in healthcare settings, 2006. Health-care Infection Control Practices Advisory Committee (HICPAC) website. http://www.cdc.gov/hicpac/mdro/mdro_toc.html. Up-dated December 29, 2009.
61. Won SY, Munoz-Price LS, Lolans K, Hota B, Weinstein RA, Hayden MK. Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis 2011;53(6):532-540.
62. Marchaim D, Chopra T, Bogan C, et al. The burden of multi-drug-resistant organisms on tertiary hospitals posed by patients with recent stays in long-term acute care facilities. Am J Infect Control 2012;40(8):760-765.
63. Tamma PD, Savard P, Pal T, Sonnevend A, Perl TM, Milstone AM. An outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2012;33(6):631-634.
64. Munoz-Price LS, Hayden MK, Lolans K, et al. Successful control of an outbreak of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae at a long-term acute care hospital. Infect Control Hosp Epidemiol 2010;31(4):341-347.
65. Naas T, Cuzon G, Babics A, et al. Endoscopy-associated transmission of carbapenem-resistant Klebsiella pneumoniae producing KPC-2 β-lactamase. J Antimicrob Chemother 2010;65(6): 1305-1306.
66. Carbonne A, Thiolet JM, Fournier S, et al. Control of a multi-hospital outbreak of KPC-producing Klebsiella pneumoniae type 2 in France, September to October 2009. Euro Surveill 2010; 15(48):pii = 19734.
67. Schechner V, Kotlovsky T, Tarabeia J, et al. Predictors of rectal carriage of carbapenem-resistant Enterobacteriaceae (CRE) among patients with known CRE carriage at their next hospital encounter. Infect Control Hosp Epidemiol 2011;32(5):497-503.
68. Passaretti CL, Otter JA, Reich NG, et al. An evaluation of environmental decontamination with hydrogen peroxide vapor for reducing the risk of patient acquisition of multidrug-resistant organisms. Clin Infect Dis 2013;56(1):27-35.
69. Lee BY, Bartsch SM, Wong KF, et al. Simulation shows hospitals that cooperate on infection control obtain better results than hospitals acting alone. Health Aff 2012;31(10):2295-2303.
70. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing gram-negative bacteria. Clin Microbiol Infect 2012; 18(5):439-448.
71. Schechner V, Kotlovsky T, Kazma M, et al. Asymptomatic rectal carriage of blaKPC producing carbapenem-resistant Enterobacteriaceae: who is prone to become clinically infected? Clin Microbiol Infect 2013;19(5):451-456.
72. Rapp RP, Urban C. Klebsiella pneumoniae carbapenemases in Enterobacteriaceae: history, evolution, and microbiology concerns. Pharmacotherapy 2012;32(5):399-407.
73. Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med 2012;27(2): 128-142.